ELIMINATE-B Phase 1 dose finding study for chronic Hepatitis B executing on schedule with completion of first dose administration for cohort 1 (n=3 patients) PBGENE-HBV, the first LNP gene editing ...

Prime Medicine announces promising preclinical results for a novel AATD treatment using advanced Prime Editing technology, aiming for clinical trials by mid-2026. Prime Medicine, Inc. announced the ...

Precision BioSciences’ most advanced cell therapy for a type of blood cancer is on track for a pivotal clinical trial, but that study is no longer its responsibility. The biotech is outlicensing ...

Eli Lilly is joining Amgen and Novartis in the pack of drugmakers aiming to treat cardiovascular disease by targeting lipoprotein(a). The Big Pharma landed a spot at the back of the bunch by handing ...

BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Broken String Biosciences (“Broken String”), a leader in advancing gene editing safety, today opened its Catalyst Early Access Program (EAP) for ...

ProQR Therapeutics advances RNA editing pipeline with upcoming CTA filing for AX-0810, while enhancing leadership and maintaining strong finances. ProQR Therapeutics N.V. announced significant ...

ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing ...

The first patient treated with Graphite Bio's gene-editing program suffered a serious side effect. The biotech halted the trial while it investigates the case, which may impact other CRISPR companies.